SCHEMBL474266

SCHEMBL474266

C1CC2CNCC2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15601035 1.00
SCHEMBL2262923 1.00
SCHEMBL9938147 1.00
SCHEMBL2262928 1.00
SCHEMBL13250365 0.93 CCR5 (0.47)
SCHEMBL1243243 0.93 CCR5 (0.47)
SCHEMBL8007981 0.93 CCR5 (0.47)
SCHEMBL2881738 0.90 CCR5 (0.53)
SCHEMBL1545962 0.90 CCR5 (0.53)
SCHEMBL17310756 0.90 CCR5 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263412-A1 NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 US claimed
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-07-10 US claimed
US-20250090524-A1 BTK INHIBITORS BIOGEN MA INC. 2025-03-20 US claimed
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 EP claimed
CN-119365454-A Discovery of covalent EGFR inhibitors through cysteine 775 丹娜-法伯癌症研究院 2025-01-24 CN claimed
CN-118984829-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2024-11-19 CN claimed
EP-4430048-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 EP claimed
EP-4308097-A1 NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE The Regents Of The University Of Michigan (US) 2024-01-24 EP claimed
EP-3430013-B1 CARBAPENEM COMPOUNDS ORCHID PHARMA LTD (IN) 2023-11-15 EP claimed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO claimed
US-7935725-B2 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA NV (BE) 2011-05-03 US claimed
CN-101909628-A As leukotriene A4Aryl substituted bridged or fused diamines as hydrolase modulators JANSSEN PHARMACEUTICA NV 2010-12-08 CN claimed
EP-2217237-A1 ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE Janssen Pharmaceutica N.V. (BE) 2010-08-18 EP claimed
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-06-03 US claimed
CN-101663293-A Quinoline-carboxamide derivatives as p2y12 antagonists SANOFI AVENTIS 2010-03-03 CN claimed
EP-2148871-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-02-03 EP claimed
WO-2009058347-A1 ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-07 WO claimed
US-20090111794-A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US claimed
WO-2008128647-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-10-30 WO claimed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US claimed